Brief: Autolus Therapeutics Collaborates With Cabaletta Bio For Autoimmune Disease Cell Therapies
09/01/2023 13:43
Jan 9 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* AUTOLUS THERAPEUTICS ANNOUNCES COLLABORATION WITH
CABALETTA BIO
FOR USE OF AUTOLUS’ SAFETY SWITCH SYSTEM IN CELL THERAPIES FOR
AUTOIMMUNE DISEASE
* AUTOLUS-IN DEAL,CO WILL RECEIVE UPFRONT PAYMENT FOR
NON-EXCLUSIVE ACCESS TO RQR8 SAFETY SWITCH FOR USE IN
CABALETTA'S CD19-CAR T CELL THERAPY PROGRAM
* AUTOLUS THERAPEUTICS PLC - IS ENTITLED TO RECEIVE
ROYALTIES ON
NET SALES OF ALL CABALETTA CELL THERAPY PRODUCTS THAT
INCORPORATE RQR8 SAFETY SWITCH
Source text for Eikon: ID:nGNX6pWZ6P
Further company coverage: AUTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity